PROMIS NEUROSCIENCES INC. Operating Expenses
PROMIS NEUROSCIENCES INC. (PMN) reported Operating Expenses of $12.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- PROMIS NEUROSCIENCES INC. operating expenses for the quarter ending 2026-06-30 was $12.27M, a 20.44% increase year-over-year.
- PROMIS NEUROSCIENCES INC. operating expenses for the quarter ending 2026-03-31 was $8.64M, a 15.88% increase year-over-year.
- PROMIS NEUROSCIENCES INC. operating expenses for the quarter ending 2025-12-31 was $10.77M, a 79.46% increase year-over-year.
- PROMIS NEUROSCIENCES INC. operating expenses for the quarter ending 2025-09-30 was $11.75M, a 164.97% increase year-over-year.
- PROMIS NEUROSCIENCES INC. operating expenses for fiscal 2025 was $40.17M, a 138.70% increase from fiscal 2024.
- PROMIS NEUROSCIENCES INC. operating expenses for fiscal 2024 was $16.83M, a 17.98% increase from fiscal 2023.
- PROMIS NEUROSCIENCES INC. operating expenses for fiscal 2023 was $14.26M, a 39.00% decline from fiscal 2022.
- PROMIS NEUROSCIENCES INC. operating expenses for fiscal 2022 was $23.38M, a 181.99% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.27M 10-Q · filed 2026-08-13 | $20.91M 10-Q · filed 2026-08-13 | $31.68M derived: sum of 3 quarters · filed 2026-08-13 | $43.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $8.64M 10-Q · filed 2026-05-12 | $19.42M derived: sum of 2 quarters · filed 2026-05-12 | $31.17M derived: sum of 3 quarters · filed 2026-05-12 | $41.35M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $10.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $22.52M derived: sum of 2 quarters · filed 2026-03-25 | $32.71M derived: sum of 3 quarters · filed 2026-08-13 | $40.17M 10-K · filed 2026-03-25 |
| 2025-09-30 | $11.75M 10-Q · filed 2025-11-12 | $21.94M derived: sum of 2 quarters · filed 2026-08-13 | $29.40M 10-Q · filed 2025-11-12 | $35.40M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $10.18M 10-Q · filed 2026-08-13 | $17.64M 10-Q · filed 2026-08-13 | $23.65M derived: sum of 3 quarters · filed 2026-08-13 | $28.08M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $7.46M 10-Q · filed 2026-05-12 | $13.46M derived: sum of 2 quarters · filed 2026-05-12 | $17.90M derived: sum of 3 quarters · filed 2026-05-12 | $20.61M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $10.44M derived: sum of 2 quarters · filed 2026-03-25 | $13.15M derived: sum of 3 quarters · filed 2026-03-25 | $16.83M 10-K · filed 2026-03-25 |
| 2024-09-30 | $4.43M 10-Q · filed 2025-11-12 | $7.15M derived: sum of 2 quarters · filed 2025-11-12 | $10.83M 10-Q · filed 2025-11-12 | $14.70M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $2.71M 10-Q · filed 2025-08-13 | $6.39M 10-Q · filed 2025-08-13 | $10.26M derived: sum of 3 quarters · filed 2025-08-13 | $12.78M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $3.68M 10-Q · filed 2025-05-12 | $7.55M derived: sum of 2 quarters · filed 2025-05-12 | $10.07M derived: sum of 3 quarters · filed 2025-05-12 | $12.97M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $3.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $6.39M derived: sum of 2 quarters · filed 2025-03-31 | $9.29M derived: sum of 3 quarters · filed 2025-03-31 | $14.26M 10-K · filed 2025-03-31 |
| 2023-09-30 | $2.52M 10-Q · filed 2024-11-14 | $5.42M derived: sum of 2 quarters · filed 2024-11-14 | $10.39M 10-Q · filed 2024-11-14 | $18.91M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $2.90M 10-Q · filed 2024-08-08 | $7.87M 10-Q · filed 2024-08-08 | $16.39M derived: sum of 3 quarters · filed 2024-08-08 | $22.45M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.97M 10-Q · filed 2024-05-14 | $13.49M derived: sum of 2 quarters · filed 2024-05-14 | $19.55M derived: sum of 3 quarters · filed 2024-05-14 | $24.41M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $8.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $14.58M derived: sum of 2 quarters · filed 2024-04-01 | $19.44M derived: sum of 3 quarters · filed 2024-04-01 | $23.38M 10-K · filed 2024-04-01 |
| 2022-09-30 | $6.05M 10-Q · filed 2023-11-14 | $10.92M derived: sum of 2 quarters · filed 2023-11-14 | $14.86M 10-Q · filed 2023-11-14 | $19.40M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $4.86M 10-Q · filed 2023-08-14 | $8.80M 10-Q · filed 2023-08-14 | $13.35M derived: sum of 3 quarters · filed 2023-08-14 | $15.42M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $3.94M 10-Q · filed 2023-05-15 | $8.49M derived: sum of 2 quarters · filed 2023-05-15 | $10.56M derived: sum of 3 quarters · filed 2023-05-15 | $11.66M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $6.62M derived: sum of 2 quarters · filed 2023-03-08 | $7.72M derived: sum of 3 quarters · filed 2023-03-08 | $8.29M 10-K · filed 2023-03-08 |
| 2021-09-30 | $2.07M 10-Q · filed 2022-11-14 | $3.18M derived: sum of 2 quarters · filed 2022-11-14 | $3.74M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $1.11M 10-Q · filed 2022-08-12 | $1.67M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |